Dr. Deborah Citrin, MD
Claim this profileNational Cancer Institute
Studies Prostate Cancer
Studies Uterine Tumors
6 reported clinical trials
10 drugs studied
Area of expertise
1Prostate Cancer
Stage III
Stage IV
2Uterine Tumors
Affiliated Hospitals
Clinical Trials Deborah Citrin, MD is currently running
18F-DCFPyL Imaging
for Prostate Cancer
Background: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help. Objective: To test how an imaging agent called 18F-DCFPyL detects response to standard prostate cancer treatment. Eligibility: People ages 18 and older with newly diagnosed prostate cancer who have no evidence of distant metastatic disease and plan to get stereotactic body radiation therapy (SBRT) with or without androgen deprivation therapy (ADT). Design: Participants will be screened with: Medical history Physical exam Blood tests MRI Participants will have baseline MRI and PET/CT scans. For the MRI, they may get a contrast agent by IV injection. For the PET/CT scan, they will get an IV injection of 18FDCFPyL. About 1 to 2 hours later, they will get the PET/CT scan. During the scans, participants will lie on their back and remain still for 45 minutes to 1 hour. These scans will be repeated at different points during the study. Participants will get SBRT with or without ADT. Participants will complete questionnaires about their quality of life. Participants will be asked about any symptoms they are having. They will also be asked about medications they are using. They may have a physical exam. Participants will give blood and urine samples. They will give a tumor sample from a biopsy they have had in the past. After treatment, participants will have follow-up visits. These will occur 1 month after treatment, then every 3 months for a year, and then every 6 months for 1 more year.
Recruiting1 award Phase 2
Electrical Stimulation
for Urinary Incontinence
Background: Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help. Objective: To see if the Elidah device can reduce urinary incontinence after prostate treatment. Eligibility: Men aged 18 years and older who have had moderate urinary incontinence for at least 6 months after treatment for prostate cancer. Design: Participants will be in the study for about 9 weeks. They will be screened. They will have a physical exam with urine tests. The Elidah device consists of a Controller and a GelPad. The Controller sets the strength of electrical impulses. The GelPad is placed against the skin under the pelvis. Participants will be given an Elidah device and taught how to use it at home. They will use the device once a day for 20 minutes at a time; they will do this 5 days a week for 6 weeks. Participants will complete a daily log. They will record the strength of electrical impulses (0-35); the number of incontinence episodes; the type of incontinence episode; and the number of used pads. Participants will do a pad weight test. For 3 days before and 3 days after using the Elidah device, they will collect all of their used pads for each 24-hour period into a sealed plastic bag. They will also collect a second set of bags that contain dry versions of each product used. Participants will have clinic visits after using the device for 3 weeks and after finishing the 6 weeks of treatment. Participants will complete 15-minute questionnaires.
Recruiting1 award Phase 28 criteria
More about Deborah Citrin, MD
Clinical Trial Related2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Deborah Citrin, MD has experience with
- 18F-DCFPyL
- Dose To Prostate Bed Irradiation Only
- Dose To Prostate Bed With Integrated Boost
- HDR Brachytherapy
- Elidah Device
- Prostate Radiation + Tumor Boost Irradiation
Breakdown of trials Deborah Citrin, MD has run
Prostate Cancer
Uterine Tumors
Endometrial Cancer
Esophageal Cancer
Cervical Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Deborah Citrin, MD specialize in?
Deborah Citrin, MD focuses on Prostate Cancer and Uterine Tumors. In particular, much of their work with Prostate Cancer has involved Stage III patients, or patients who are Stage IV.
Is Deborah Citrin, MD currently recruiting for clinical trials?
Yes, Deborah Citrin, MD is currently recruiting for 3 clinical trials in Bethesda Maryland. If you're interested in participating, you should apply.
Are there any treatments that Deborah Citrin, MD has studied deeply?
Yes, Deborah Citrin, MD has studied treatments such as 18F-DCFPyL, Dose to prostate bed irradiation only, Dose to prostate bed with integrated boost.
What is the best way to schedule an appointment with Deborah Citrin, MD?
Apply for one of the trials that Deborah Citrin, MD is conducting.
What is the office address of Deborah Citrin, MD?
The office of Deborah Citrin, MD is located at: National Cancer Institute, Bethesda, Maryland 20894 United States. This is the address for their practice at the National Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.